Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Netherlands

    - PMLiVE

    Boehringer Ingelheim and CDR-Life agree on deal worth up to $570m

    The deal focuses on T cell-based therapies for autoimmune disease

    - PMLiVE

    AbbVie shares promising phase 3 results for Rinvoq in severe alopecia areata

    Around 700,000 people in the US are living with some form of the autoimmune disease

    - PMLiVE

    BMS and Bain Capital launch new company to develop immunology therapies

    The newly formed company has in-licensed five investigational immunology drugs from BMS

    - PMLiVE

    AbbVie gains rights to IGI’s phase 1 trispecific engager in deal worth over $1.9bn

    ISB 2001 is in early-stage clinical development for relapsed/refractory multiple myeloma

    - PMLiVE

    Boehringer and Cue partner to advance autoimmune disease candidate in deal worth $357m

    The B cell depletion therapy has the potential to reach patients earlier in their treatment journeys

    - PMLiVE

    AbbVie’s Rinvoq receives EC approval to treat adults with giant cell arteritis

    The drug is now the first oral JAK inhibitor to be approved in the EU for this patient population

    - PMLiVE

    Pfizer and Flagship Pioneering enter autoimmune disease partnership

    More than 100 known types of autoimmune diseases affect over 50 million people in the US

    - PMLiVE

    Sanofi expands immunology pipeline by acquiring Dren’s bispecific for $600m upfront

    The candidate has shown potential in treating B-cell mediated autoimmune diseases

    - PMLiVE

    J&J’s nipocalimab granted FDA breakthrough designation for Sjögren’s disease

    The chronic autoimmune disease affects approximately four million people globally

    - PMLiVE

    GSK expands immunology pipeline by acquiring Chimagen’s CMG1A46 in deal worth $850m

    The company plans to develop the candidate for autoimmune diseases such as lupus

    - PMLiVE

    J&J’s nipocalimab shows sustained disease control in adolescents with generalised myasthenia gravis

    The severity of the rare autoimmune disease is heightened in paediatric patients

    - PMLiVE

    Johnson & Johnson shares positive phase 3 results for nipocalimab in myasthenia gravis

    The rare autoimmune disease is estimated to affect around 700,000 people globally

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links